Abstract:Background: Mutations in DNA Damage Response (DDR) genes, including those resulting in loss of Ataxia-Telangiectasia, Mutated (ATM) expression are common in advanced prostate cancers (PC). Poly (ADP-ribose) polymerase (PARP) inhibitors are approved in this setting but demonstrate limited clinical efficacy in ATM-mutant PCs. In this project, we sought to define the impact of ATM loss on DDR pathways in PC, with the goal of identifying alternate therapeutic vulnerabilities. Methods: ATM-KO PC cell lines were generated via CRISPR-Cas9. ATM loss and attenuation of downstream kinase activity were confirmed via western blot. Phosphoproteomic evaluation in parental and ATM-KO cells was performed following ionizing radiation (IR). Clonogenic survival assays were performed after treatment with inhibitors and/or IR. Kinetics of DDR foci recruitment and resolution were interrogated with immunofluorescence (IF). DNA fiber assays were utilized to assess replication stress. Results: ATM-KO PC cells were able to effectively repair DNA damage following IR, as measured by resolution of yH2ax, 53BP1, and MDC1 foci. Phosphoproteomic studies indicated that ATM-KO cells maintained canonical DDR pathways through activation of ATR and DNA-PKcs kinases. Treatment of ATM-KO cells with either the ATR inhibitor VX970 or the DNA-PKcs inhibitor M3814 incrementally affected DDR in ATM-KO cells compared to ATM-proficient parental control cells. Importantly, combination treatment with VX970 and M3814 was needed to prevent downstream DDR foci recruitment in ATM-KO cells and was more effective in radiosensitizing ATM-KO PC than either parental control cells or single drug treatment. These data indicate that the activity of any one of the trinities of these kinases is sufficient to mediate DDR and that blockade of both ATR and DNA-PKcs is needed to effectively prevent DDR in ATM-KO PC. Further, DNA fiber assays showed significantly decreased fork length with dual treatment compared to control or single drug, indicating increased replication stress. We then leveraged a RUVBL1 ATPase inhibitor Compound B, which affects the expression of these three kinases. In ATM-KO PC cells, Compound B attenuated ATR and DNA-PKcs expression and radiosensitized the cells as shown by clonogenic survival assays. DNA fiber assays indicated that Compound B induced replication stress in ATM-KO PC cells to the same extent as combination therapy. In combination with IR, Compound B also significantly attenuated the growth of ATM-KO PC xenografts in vivo. Conclusions: Our unbiased phosphoproteomic approach indicated that ATR and DNA-PKCs mediate DDR following IR in ATM-KO PC cells, and that dual targeting of both ATR and DNA-PKcs is necessary to block DDR in ATM-KO PC cells. We have identified that Compound B effectively depletes ATR and DNA-PKcs, sensitizes to DNA damage, and induces replication stress in ATM-KO PCs. Our studies suggest that Compound B may be a novel therapeutic strategy in ATM-mutant PC. Citation Format: Mia E. Hofstad, Lan Yu, Andrea Woods, Zoi E. Sychev, Alice Mazzagatti, Xiaofang Huo, Ralf Kittler, Peter Ly, Justin M. Drake, Ganesh V. Raj. Deciphering DNA damage repair in ATM mutant prostate cancers [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: DNA Damage Repair: From Basic Science to Future Clinical Application; 2024 Jan 9-11; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2024;84(1 Suppl) nr A020.

Functionally-instructed modifiers of response to ATR inhibition in experimental glioma

Evidence of Improving Therapeutic Outcomes

Targeting ATR in patients with cancer

ATR kinase inhibitors NVP-BEZ235 and AZD6738 effectively penetrate the brain after systemic administration

DNAR-13. TARGETING THE DNA DAMAGE RESPONSE IN GLIOBLASTOMA PROPAGATING CELLS: FROM MOLECULAR MECHANISMS TO PRECISION MEDICINE

ATR inhibition radiosensitizes cells through augmented DNA Damage and G2 cell cycle arrest abrogation

IMMU-34. ATRX MUTATIONS PREDICT RESPONSE TO INNATE BASED THERAPY IN GLIOMA

Interplay between ATRX and IDH1 mutations governs innate immune responses in diffuse gliomas

BRAT1 - a new therapeutic target for glioblastoma

DNA Damage Response Evaluation Provides Novel Insights for Personalized Immunotherapy in Glioma

DNA damage response in brain tumors: A Society for Neuro-Oncology consensus review on mechanisms and translational efforts in neuro-oncology

Abstract A020: Deciphering DNA damage repair in ATM mutant prostate cancers

New insight into targeting the DNA damage response in the treatment of glioblastoma

Recent Advances in Synergistic Antitumor Effects Exploited from the Inhibition of Ataxia Telangiectasia and RAD3-Related Protein Kinase (ATR)

Recent developments in drug delivery strategies for targeting DNA damage response in glioblastoma

Glycometabolic reprogramming-induced XRCC1 lactylation confers therapeutic resistance in ALDH1A3-overexpressing glioblastoma

Abstract B022: Interplay between the cellular dntp pool and dna double-strand break repair: a potential therapeutic target for refractory glioblastoma

First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors

Inhibition of H3K27M-enhanced ATM signaling increases radiation efficacy in diffuse midline glioma

Discovery of Preclinical Candidate AD1058 as a Highly Potent, Selective, and Brain-Penetrant ATR Inhibitor for the Treatment of Advanced Malignancies

Genetic vulnerabilities upon inhibition of DNA damage response